Key Takeaways:
Priovant initiated a new Phase 2b/3 trial for its drug brepocitinib to treat Lichen Planopilaris, a scalp disorder affecting 100,000 US adults.
According to a company announcement on April 2, 2026, the first subjects for the potentially registrational trial were enrolled in March 2026.
Lichen planopilaris is a severe condition causing irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations. Currently, no FDA-approved therapies exist for the disorder.
The advancement into a late-stage trial for an indication with no approved treatments is a significant de-risking event for Priovant. Success could open a new market and bolster investor confidence in the company's drug pipeline.
Brepocitinib's development in this area is supported by what the company described as clinically meaningful results in a prior investigator-initiated, placebo-controlled study. LPP is now the fourth indication in the drug's expanding late-stage development program.
The initiation of this potentially registrational trial is a critical step toward addressing a high unmet medical need. Investors will be closely watching for interim data readouts and the ultimate results, which could create a significant future revenue stream for Priovant if successful.
This article is for informational purposes only and does not constitute investment advice.
